Cryo-Cell International Inc. (CCEL)

From the record

Cryo-Cell International Inc.'s filings since 2017 show 6 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-05-08); an auditor change (8-K item 4.01, the latest 2019-10-02); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2023-04-14) (its current reports).

From the record

Cryo-Cell International Inc.'s 9 filed years say what it did: revenue went from $25 million in fiscal 2017 to $32 million in fiscal 2025, up 2.8% a year; it rose in 5 of 8 years; the deepest fall was 9% from fiscal 2019 to fiscal 2021; net income was positive in 6 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-11-30, Cryo-Cell International Inc.'s diluted share count shrank about 1.7% a year, and dividends and buybacks returned about 37% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-10-28 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-11-30, Cryo-Cell International Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 39 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 130 cents per dollar of assets, and net share issuance: its share count shrank 1.8% over the year (the filed statements).

From the record

Cryo-Cell International Inc.'s standing among 10 graded names in its industry family: revenue of $32 million in fiscal 2025 ranks in the bottom 39% by size; a net margin of -7.7% ranks in the bottom 25%; revenue growth of 1.3% a year over the last 3 filed years ranks in the bottom 25% (its annual reports).

From the record

Cryo-Cell International Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Portnoy, David (Chairman, Co-CEO, as filed), filing under that title since 2011-09-02, 15.2 years (top 6% of its family); the 6 officers and directors filing in the last fifteen months have been on the record a median of 15.2 years (top 7%); no officer or director change was reported on Form 8-K since 2023-11-13, against the 6 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Cryo-Cell International Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $319 thousand against debt of $8 million leaves -13% of its assets as net cash, bottom 35% of its family; cash from operations less capital spending is 16.6% of revenue (top 5%); a gross margin of 76.6% (top 19%); research spending of 1.2% of revenue (top 30%) (its annual report).

From the record

Cryo-Cell International Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.3% a year over the last three filed years against 2.8% over all 9, slowing (top 45% of its family); the newest year grew -1.3% (bottom 45%); research spending grew -0.7% a year (bottom 38%); capital spending grew -73.3% a year (bottom 15%) (its annual reports). Cryo-Cell International Inc. reported 3 lines of business in fiscal 2025: Umbilical Cord Blood and Cord Tissue Stem Cell Service at $31 million (99%), Public Cord Blood Banking at $130 thousand (0%), Prepacytecb at $54 thousand (0%); 0 of 3 grew against the year before (its annual report).

From the record

Cryo-Cell International Inc.'s newest year against its own record: revenue of $32 million in fiscal 2025 came in 3.9% below the $33 million its prior three years' pace pointed to (top 35% of its family); net income of $2 million against a prior three-year average of $2 million (bottom 35%); a net margin of -7.7% against -6.7% before (bottom 15%) (its annual reports).